Movement Disorders

Experts discuss different strategies to manage concerns relating to advanced Parkinson disease including patient education.

A discussion about how to educate and speak with patients with advanced Parkinson disease.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.

Michael J. Soileau, MD, discusses how to recognize when a patient has advanced Parkinson disease, what are the initial or relevant signs and symptoms of advanced disease, and how patients shift from early to intermediate and advanced disease.

Joohi Jimenez-Shahed, MD, describes the natural progression of Parkinson disease from the time of diagnosis to advanced disease.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

Aristide Merola, MD, PhD, leads a discussion about the burden and impairment on the quality of life for patients with advanced Parkinson disease.

Experts in the field of Parkinson disease kick off a discussion about recognizing and managing the disease by defining advanced Parkinson disease.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

Bayer provided an update on their phase 1 and 1b studies of dopaminergic neurons and GDNF gene therapy, respectively, for the treatment of PD.

Despite a few surprising program failures early this year, there is plenty of potential worth holding on to in the Huntington disease pipeline.

Here's what is coming soon to NeurologyLive.

When paired with the Percept PC device, SenSight expands on BrainSense technology, enabling clinicians to capture and record enhanced, directional local field potential information from the implanted lead.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

For patients treated with pimavanserin in investigational doses of 8.5 mg or 17 mg in the previous studies, further improvement was observed during the open-label extension with 34-mg pimavanserin.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

Serum tumor necrosis factor and glutathione levels decreased, and brain-derived neurotrophic factor levels increased significantly after treatment with electroCore’s gammaCore nVNS device.